
Documentary drives home seriousness of heart attacks among South Asians
The two medical school sweethearts and senior physicians from Pennsylvania with over 70 years of medical practice set out to uncover what was behind this increasing loss of life. In the process, they met more than 40 heart specialists ,well-known actors and directors to now release a documentary drama called The Brown Heart.
Released in May this year, the film unites voices from across fields to spark awareness and change and confronts this crisis head-on through real-life stories and expert insights. Heart attacks are a significant health concern, particularly in South Asia where the risk of cardiovascular disease is high and tends to occur earlier in life. According to the World Health Organisation, this premature onset of heart disease is attributed to a combination of genetic factors, lifestyle choices and environmental factors.
Dr Nirmal Joshi recalled how Renu and he would discuss the issue and decided to undertake this journey two years ago. 'We travelled to India, USA and UK to gather human stories of survival and loss related to the menace of heart disease in South Asians (from India, Pakistan, Bangladesh, Srilanka and Nepal). We were able to weave over 100 hours of these interviews into a two-hour documentary film,' Dr Joshi said, adding that a longer version with four 45-minute episodes in the form of a web-series has also been taken up.
Dr Joshi, who had earlier written and directed The Hippocratic Oath, a 45-minute digital film that was used for educating doctors in training across the United States, also directed the professional short film Goodnight Giggles that was selected in the Satyajit Ray short film competition at the London Indian Film Festival in November 2023. Dr Renu Joshi, who was also Vice-President of Population Health and Diabetes at University of Pittsburgh Medical Center, participated actively in the unique venture.
The duo soon connected with Yogendra Singh as the film's associate director. This ambitious project received donations from private donors in Central Pennsylvania but the majority of funding was provided by two couples Hersha and Hasu P Shah and Madhavi and Ramesh Bathini. While in India, the senior doctors travelled to Pune and spent an entire day at the Diabetes Research Unit at KEM Hospital Pune. Dr C S Yajnik, director of the unit who is well-known for his research on the `thin-fat' Indian phenotype said that it was a great effort taken and the film was a one-stop compendium of factors associated with heart attack in young Indians..
Dr Yajnik also encouraged the Joshi's to create 15-minute documentaries with simple, easy-to-understand messages aimed at students in schools and colleges.'This will reinforce the importance of guiding youngsters to take concrete steps to improve their lifestyle, get necessary tests done to assess their risk of future health problems. This is the need of the hour,' he added.
The Brown Heart premiered recently on JioHotstar and according to Dr Joshi, they embarked upon this unique venture hoping to bring about a change. 'Even if we can inspire a small percentage of viewers to change after watching the film, our hard work would have been worth it,' Dr Joshi said.
Anuradha Mascarenhas is a journalist with The Indian Express and is based in Pune. A senior editor, Anuradha writes on health, research developments in the field of science and environment and takes keen interest in covering women's issues. With a career spanning over 25 years, Anuradha has also led teams and often coordinated the edition.
... Read More
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
30 minutes ago
- Time of India
Sangli doc told to pay Rs7.5L for med negligence causing death
Kolhapur: A doctor in Sangli has been ordered by the district consumer court to pay Rs7.5 lakh to the mother of a four-year-old girl who died after receiving treatment. The court ruled that the doctor provided "deficient service" by failing to perform necessary tests before beginning treatment. The incident occurred about seven years ago when the girl, Avantika Sagar Sale, was admitted to the hospital run by paediatrician Vidyadhar Patil. Her mother, Sheetal, claimed that her daughter's death was caused by a delay in receiving the correct treatment. On Aug 14, the consumer court ordered the doctor to make the payment with interest from the date the complaint was filed. The doctor was also ordered to pay an additional Rs1 lakh for mental anguish and Rs 20,000 towards legal costs. Shailendra Kelkar, advocate for the complainant mother, said, "This case was rare since the treatment was carried out without relevant tests. The symptoms clearly indicated dengue or malaria, but the specific tests were not carried out despite laboratories being available in the town. Even after the platelet count declined rapidly, the doctor went ahead with the treatment without understanding the cause. It was a fit case of medical negligence. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Kumbarahalli Users Prefers Toothsi Aligners Toothsi by MakeO Book Now Undo " Shalivahan Pattanshetti, a Jat-based MD doctor, testified before the commission. He also said that without tests, treatment cannot be carried out as a basic thumb rule in the profession. The commission found that the paediatrician carried out the treatment considering the illness as viral infection. TOI tried to reach the paediatrician, but he was not available for comment. Legal experts said that in such cases, the defendant can settle the case by paying a compensation as per the judgment delivered by the commission or challenge it before the state consumer disputes redressal commission. Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.


Time of India
an hour ago
- Time of India
ICMR DG calls for building collective narrative to tackle common health issues in South Asia
New Delhi: Pushing towards cross-border collaborations and knowledge-partnerships among South Asian nations, Dr Rajiv Bahl, DG, Indian Council of Medical Research (ICMR), expressed that it's time to build and focus own narrative to address the region's common public health challenges. Speaking at the international meet on public health research hosted by the ICMR and Department of Health Research (DHR), Dr Bahl said that, 'the issues we face are common to all of us, and it is time for our region to move towards shaping its own narrative.' 'By learning from each other's research ecosystems, we can build stronger systems, generate knowledge that reflects our realities, and translate it into better health for our people,' he added. Present at the event, Dr VKPaul, Member, NITI Aayog further outlined that, 'By working together, we can accelerate progress towards achieving Sustainable Development Goals across the region and there is tremendous scope to co-create research products, and translate science into action.' The two day 'International Meeting on Health Research and Innovations in Public Health' is part of the Regional Enabler for South and Southeast Asia Research for Health (RESEARCH) Platform, which aims to promote, knowledge-sharing, and collaboration across innovators from South and Southeast Asian nations, the release stated. Under the first-of-its-kind gathering, countries have signalled their intent to co-create solutions, improve public health and accelerate progress towards universal health coverage, it added.


Mint
4 hours ago
- Mint
Layoffs loom at weight loss drug Wegovy's maker Novo Nordisk as slowing sales threaten job cuts
COPENHAGEN, Aug 21 (Reuters) - As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff numbers over five years. Now sales are slowing and layoffs loom. Annual reports show that Novo's workforce grew from around 43,260 employees in 2019 to 77,350 by the end of last year - an average of 131 new roles filled each week, far faster than rival Eli Lilly, whose headcount rose from 36,000 to 47,000 over the same period. Novo's rapid expansion is now under scrutiny from investors and even management, with the drugmaker facing cost pressure and heightened competition from Lilly's Zepbound and cheaper weight loss copycat compounds in the United States. "I don't want to limit myself in terms of where I look for savings, and salaries are a cost item. I will go through everything," said CEO Maziar Mike Doustdar on August 7, his first day in the job. Two weeks later, on Wednesday, Novo said it had implemented a global hiring freeze for non-critical roles. When asked for details of headcount reduction plans, a company spokesperson referred Reuters to Doustdar's comments. The five-year hiring surge saw employee costs almost double to nearly $9.9 billion by last year, company filings show. While the increased overhead barely registered as sales shot up, Novo's gross margin has been squeezed this year, reaching its lowest level in two and a half years in the second quarter. The stock market has wiped $490 billion off the company's market capitalisation since a peak last year when it was Europe's most valuable firm. It appointed Doustdar to turn things around after twice warning on profit this year and saying sales could dip in the second half of 2025 from a year earlier. "Their earnings had been so strong that you could ignore the cost side," said Lars Hytting, head of trading at Denmark-based investment firm ArthaScope, which holds Novo shares, adding the firm had grown "complacent" and now needed to slim down. 'Novo is now going on Wegovy.' SALES JOBS SEEN AT RISK Some analysts anticipate layoffs in the sales division - a common industry cost-cutting measure. Novo hinted at this during its second-quarter results, saying it would begin deprioritising sales of Rybelsus, its older type 2 diabetes treatment. Sales of the drug have declined, eclipsed by soaring demand for Ozempic, which shares the same active ingredient as Wegovy. "That is probably not a coincidence," said TD Cowen analyst Michael Nedelcovych. "When companies try to cut costs, they probably look first to a sales force for an ailing drug." Novo built a new U.S. sales force to market Wegovy to doctors rather than rely on staff who were already promoting Ozempic, three former employees familiar with the drug's launch told Reuters. That meant more costs, and at times the teams overlapped in outreach to the same healthcare providers, they said. All asked not to be named in order to speak frankly about a former employer. The Novo Nordisk spokesperson declined to comment on the structure of its business. In response to the initial unprecedented demand for Wegovy, Novo also invested billions to expand factories in Denmark and the United States. The company said in early 2024 that around 70% of new hires in the previous two to three years were in the manufacturing division. The spokesperson said that last year, 49% of new hires were related to manufacturing, including around 3,200 employees from Catalent, a contract drugmaker acquired last year by Novo Holdings, Novo Nordisk's controlling shareholder. Novo could also first turn to functions such as communications or administrative roles for cuts, because reductions in sales or manufacturing could hinder its ability to regain market share, said Simon Birkso Larsen, founder and head of Pipeline Clarity, a Copenhagen-based pharmaceutical industry consultancy that does not count Novo as a client. Larsen was a Novo Nordisk employee from 2015 to 2017. "Novo hired so rapidly that it has become difficult to figure out who does what in the are limits to how many people you can integrate and still be effective," he said. ($1 = 6.3995 Danish crowns) (Reporting by Maggie Fick and Jacob Gronholt-Pedersen; Editing by Adam Jourdan, Michele Gershberg and Kirsten Donovan) Disclaimer: This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.